PTO/SB/08B (08-03)
Approved for use through 7/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
ander the Paperwork Reacting with 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute for form 1449B/PTO  INFORMATION DISCLOSURE				Application Number	10/048,046	
					January 24, 2002	
STATEMENT BY APPLICANT				First Named Inventor	Halazonetis et al.	
(Use as many sheets as necessary)				Group Art Unit	1642	
				Examiner Name	M. Davis	
Sheet	<del>Ì</del> 1	of	1	Attorney Docket Number	WST97AUSA	

	-	NONPATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1 Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item, (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		T²		
40	BV	BV HALAZONETIS, T.D., "Constitutively active DNA damage checkpoint pathways a the driving force for the high frequency of p53 mutations in human cancer", DNA Repair (Amst). AugSept. 2004 3(8-9):1057-1062			
(	BW	HUYEN et al., "Structural differences in the DNA binding domains of human p53 and its C. elegans ortholog Cep-1", Structure (Camb). July 2004 12(7):1237-1243			
	BX	MARIATOS et al., "Inactivating mutations targeting the <i>chfr</i> mitotic checkpoint gene in human lung cancer", <i>Cancer Res.</i> November 1, 2003 63(21): 7185-7189			
	BY	MOCHAN et al., "53BP1, an activator of ATM in response to DNA damage", DNA Repair (Amst). AugSept. 2004 3(8-9):945-952			
	BZ	MOCHAN et al., "53BP1 and NFBDI/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage", Cancer Res. December 15, 2003 63(24): 8586-8591			
/	CR	STAVRIDI et al., "p53 and stress in the ER", Genes Dev. February 1, 2004 18(3):241-244			
<b>√</b>	CS	VENERE et al., "Chk2 leaves the PML depot", Nature Cell Biol. November 2002 4(11):E255-E256			

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not
concidered. Include carry of this form with next communication to applicable.
Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the

DAVIS

**Examiner Signature** 

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 USC 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETE FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

Considered